Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer

Anticancer Research

Volumn 31, Issue 11, 2011, Pages 3843-3849

  Cho, Yong Beom ^a   Chung, Hyuk Jun ^b   Lee, Woo Yong ^a   Choi, Sung Ho ^c   Kim, Hee Cheol ^a   Yun, Seong Hyeon ^a   Chun, Ho Kyung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Isu Abxis Co Ltd   (South Korea)

Author keywords

Adenosine triphosphate; Colorectal neoplasm; Drug screening assay; ERCC1; Thymidylate synthase

Indexed keywords

ADENOSINE TRIPHOSPHATE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; MESSENGER RNA; OXALIPLATIN; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SIGNET RING CELL; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMIDYLATE SYNTHASE;

EID: 83055191338     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004. (Pubitemid 41095086)
2. Marsh S and McLeod HL: Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer 1: 175-178; discussion 179-181, 2001.
3. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
4. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV and Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304, 2001. (Pubitemid 33096777)
5. Lehman NL: Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin Investig Drugs 11: 1775-1787, 2002.
6. Houghton JA, Tillman DM and Harwood FG: Ratio of 2′-deoxyadenosine- 5′-triphosphate/thymidine-5′-triphosphate influences the commitment of human colon carcinoma cells to thymineless death. Clin Cancer Res 1: 723-730, 1995.
7. Raymond E, Faivre S, Chaney S, Woynarowski J and Cvitkovic E: Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1: 227-235, 2002.
8. Raymond E, Faivre S, Woynarowski JM and Chaney SG: Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25: 4-12, 1998. (Pubitemid 28248696)
9. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD and Somerfield MR: American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22: 3631-3638, 2004. (Pubitemid 41103670)
10. Brown E and Markman M: Tumor chemosensitivity and chemoresistance assays. Cancer 77: 1020-1025, 1996. (Pubitemid 26080889)
11. Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, Cree IA, Hepp H and Untch M: Correlation of drug response with the ATP tumor chemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 77: 258-263, 2000. (Pubitemid 30317146)
12. Kawamura H, Ikeda K, Takiyama I and Terashima M: The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer. Eur J Cancer 33: 960-966, 1997.
13. Kang SM, Park MS, Chang J, Kim SK, Kim H, Shin DH, Chung KY, Kim DJ, Sohn JH, Choi SH, Kim J, Yoon EJ and Kim JH: A feasibility study of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) as a chemosensitivity test for lung cancer. Cancer Res Treat 37: 223-227, 2005.
14. Huh JW, Park YA, Lee KY and Sohn SK: Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer-secondary publication. Yonsei Med J 50: 697-703, 2009.
15. Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EM, Subedi AM, James EA, Dewar JA, Preece PE, Andreotti PE and Bruckner HW: Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs 7: 630-635, 1996. (Pubitemid 26348840)
16. Kim JH, Lee KW, Kim YH, Lee KH, Oh do Y, Kim J, Yang SH, Im SA, Choi SH and Bang YJ: Individualized tumor response testing for prediction of response to paclitaxel and cisplatin chemotherapy in patients with advanced gastric cancer. J Korean Med Sci 25: 684-690, 2010.
17. Cho YB, Lee WY, Song SY, Choi SH, Shin HJ, Ahn KD, Lee JM, Kim HC, Yun SH and Chun HK: In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA). Eur J Surg Oncol 35: 951-956, 2009.
18. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
19. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I and de Gramont A: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-2351, 2004. (Pubitemid 38702845)
20. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000. (Pubitemid 30644117)
21. Edler D, Blomgren H, Allegra CJ, Johnston PG, Lagerstedt U, Magnusson I and Ragnhammar P: Immunohistochemical determination of thymidylate synthase in colorectal cancer-methodological studies. Eur J Cancer 33: 2278-2281, 1997. (Pubitemid 28123422)
22. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP and Leichman CG: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4: 1243-1250, 1998. (Pubitemid 28213336)
23. Popat S, Matakidou A and Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22: 529-536, 2004. (Pubitemid 41079782)
24. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994. (Pubitemid 24379651)
25. Yamachika T, Nakanishi H, Inada K, Tsukamoto T, Kato T, Fukushima M, Inoue M and Tatematsu M: A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82: 70-77, 1998. (Pubitemid 28070481)
26. Takenoue T, Nagawa H, Matsuda K, Fujii S, Nita ME, Hatano K, Kitayama J, Tsuruo T and Muto T: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 7: 193-198, 2000. (Pubitemid 30215157)
27. Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P and Blomgren H: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20: 1721-1728, 2002. (Pubitemid 34273259)
28. Takamura M, Nio Y, Yamasawa K, Dong M, Yamaguchi K and Itakura M: Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives. Anticancer Drugs 13: 75-85, 2002. (Pubitemid 34169530)
29. Zheng Z, Li X, Schell MJ, Chen T, Boulware D, Robinson L, Sommers E and Bepler G: Thymidylate synthase in situ protein expression and survival in stage I non small cell lung cancer. Cancer 112: 2765-2773, 2008. (Pubitemid 351969222)
30. Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, Yu L, Rosell R and Liu B: ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 98: 1398-1402, 2008. (Pubitemid 351543582)
31. Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ and Kim HJ: Prognostic value of ERCCl, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol 32: 38-43, 2009.
32. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS and Kim HJ: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18: 504-509, 2007. (Pubitemid 46359630)
33. Koopman M, Venderbosch S, van Tinteren H, Ligtenberg MJ, Nagtegaal I, Van Krieken JH and Punt CJ: Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer 45: 1999-2006, 2009.
34. Booton R, Ward T, Ashcroft L, Morris J, Heighway J and Thatcher N: ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2: 902-906, 2007. (Pubitemid 47511592)